DK2632452T3 - Forbindelser og sammensætninger til cancerbehandling - Google Patents

Forbindelser og sammensætninger til cancerbehandling Download PDF

Info

Publication number
DK2632452T3
DK2632452T3 DK11856486.3T DK11856486T DK2632452T3 DK 2632452 T3 DK2632452 T3 DK 2632452T3 DK 11856486 T DK11856486 T DK 11856486T DK 2632452 T3 DK2632452 T3 DK 2632452T3
Authority
DK
Denmark
Prior art keywords
compound
cancer
formula
mmol
compounds
Prior art date
Application number
DK11856486.3T
Other languages
English (en)
Inventor
Lyne Gagnon
Brigitte Grouix
Pierre Laurin
Christopher Penney
Boulos Zacharie
Lilianne Geerts
Original Assignee
Prometic Pharma Smt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Pharma Smt Ltd filed Critical Prometic Pharma Smt Ltd
Application granted granted Critical
Publication of DK2632452T3 publication Critical patent/DK2632452T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/84—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/18—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/48—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/18—Saturated compounds containing keto groups
    • C07C62/20—Saturated compounds containing keto groups with a saturated six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (13)

1. Forbindelse repræsenteret ved Formel IC, eller et farmaceutisk acceptabelt salt deraf, til anvendelse i en fremgangsmåde til behandling af cancer hos et individ, der fortrinsvis er en human patient, med behov derfor:
Formula JC hvor n er 2, 3, 4, 5 eller 6; R er-C(O)-, -OC(O)-, -CH(OH)-, NH, NCi-C3-alkyl, O eller S; A er (CH2)mC(O)OH, W(CH2)mC(O)OH, eller YCH(C(O)OH)(CH2)PCH3, når B er H; B er (CH2)mC(O)OH, W(CH2)mC(O)OH eller YCH(C(O)OH)(CH2)PCH3, når A er H; eller A og B er kovalent bundet for at danne en 5-, 6- eller 7-leddet cycloalkyl substitueret med en C(O)OH-gruppe; WerO, S, eller NH; Yer O, S, NH eller CH2; m erO, 1, eller 2; og p er 1,2, 3, 4, 5, 6 eller 7.
2. Forbindelse til anvendelse ifølge krav 1, hvor det farmaceutisk acceptable salt er et baseadditionsalt, hvor baseadditionssaltet fortrinsvis omfatter en metalmodion, der fortrinsvis er natrium, kalium, magnesium, calcium eller lithium, og mere fortrinsvis er metalmodionen natrium.
3. Forbindelse til anvendelse i en fremgangsmåde til behandling af cancer hos et individ, der fortrinsvis er en human patient, med behov derfor, hvor forbindelsen er valgt fra gruppen bestående af:
4. Forbindelse til anvendelse ifølge krav 3, hvor forbindelsen er Forbindelse XVII eller XX, og mere fortrinsvis forbindelsen er Forbindelse XVII.
5. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor canceren er blærecancer, brystcancer, colorektalcancer, nyrecancer, melanom, ikke-Hodgkins lymfom, leukæmi, ovariecancer, pankreascancer, prostatscancer eller uteruscancer.
6. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor canceren er brystcancer, colorektalcancer, leukæmicancer, melanomcancer eller pankreascancer.
7. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor forbindelsen anvendes i kombination med et anticancermiddel, hvor anticancermidlet fortrinsvis er decarbazin, doxorubicin, daunorubicin, cyclophosphamid, busulfex, busulfan, vinblastin, vineristin, bleomycin, etoposid, topotecan, irinotecan, taxoter, taxol, 5-fluorouracil, methotrexat, gemcitabin, cisplatin, carboplatin eller chlorambucil.
8. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor forbindelsen har én eller flere af følgende biologiske aktiviteter hos individet: stimulering og/eller forbedring af IL-12-produktion ved inflammatoriske tilstande; stimulering af cytolytisk antitumoraktivitet for lymfocytter og/eller NK-celler; inducering af regression af etablerede tumorer og/eller af primære solide tumorer; hæmning af TGF-induceret CTGF-produktion; og/eller hæmning af CTGF-medierede aktiviteter.
9. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor forbindelsen hæmmer tumorcellemigration og etablering af metastase.
10. Farmaceutisk sammensætning, der omfatter en forbindelse repræsenteret ved Formel IC som defineret i et hvilket som helst af kravene 1 til 4, eller et farmaceutisk acceptabelt salt deraf, og en farmaceutisk acceptabel bærer, til anvendelse i en fremgangsmåde til behandling af cancer hos et individ med behov derfor.
11. Farmaceutisk sammensætning til anvendelse ifølge krav 10, hvor anvendelsen i behandling af cancer indbefatter inducering af regression af etablerede tumorer og/eller af primære solide tumorer.
12. Farmaceutisk sammensætning til anvendelse ifølge krav 10, hvor anvendelsen i behandling af cancer indbefatter hæmning af tumorcellemigration og etablering af metastase.
13. Farmaceutisk sammensætning til anvendelse ifølge et hvilket som helst af kravene 10 til 12, hvor sammensætningen endvidere omfatter et anticancermiddel, hvor anticancermidlet fortrinsvis er decarbazin, doxorubicin, daunorubicin, cyclophosphamid, busulfex, busulfan, vinblastin, vineristin, bleomycin, etoposid, topotecan, irinotecan, taxoter, taxol, 5-fluorouracil, methotrexat, gemcitabin, cisplatin, carboplatin og chlorambucil.
DK11856486.3T 2010-10-27 2011-10-26 Forbindelser og sammensætninger til cancerbehandling DK2632452T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40706910P 2010-10-27 2010-10-27
PCT/CA2011/001179 WO2012097427A1 (en) 2010-10-27 2011-10-26 Compounds and compositions for the treatment of cancer

Publications (1)

Publication Number Publication Date
DK2632452T3 true DK2632452T3 (da) 2019-01-21

Family

ID=46515034

Family Applications (2)

Application Number Title Priority Date Filing Date
DK11856486.3T DK2632452T3 (da) 2010-10-27 2011-10-26 Forbindelser og sammensætninger til cancerbehandling
DK18191792.3T DK3443957T3 (da) 2010-10-27 2011-10-26 Forbindelser og sammensætninger til behandling af cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK18191792.3T DK3443957T3 (da) 2010-10-27 2011-10-26 Forbindelser og sammensætninger til behandling af cancer

Country Status (25)

Country Link
US (2) US9114118B2 (da)
EP (2) EP2632452B1 (da)
JP (2) JP6007186B2 (da)
KR (2) KR101821646B1 (da)
CN (2) CN103347509B (da)
AU (2) AU2011356583C1 (da)
BR (1) BR112013010507A2 (da)
CA (1) CA2816093C (da)
CL (1) CL2013001152A1 (da)
DK (2) DK2632452T3 (da)
EA (2) EA030038B1 (da)
ES (2) ES2703257T3 (da)
HK (1) HK1189836A1 (da)
IL (2) IL225599A (da)
MX (2) MX365807B (da)
MY (2) MY184343A (da)
NZ (1) NZ610851A (da)
PH (1) PH12016502324A1 (da)
PL (2) PL2632452T3 (da)
PT (2) PT3443957T (da)
SG (2) SG189538A1 (da)
TR (1) TR201819987T4 (da)
TW (2) TWI620563B (da)
WO (1) WO2012097427A1 (da)
ZA (1) ZA201303035B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103347509B (zh) * 2010-10-27 2016-06-08 普罗米蒂克生物科学公司 用于治疗癌症的化合物和组合物
TWI742541B (zh) * 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
RU2560702C1 (ru) * 2014-06-05 2015-08-20 Общество с ограниченной ответственностью "Научно-производственный центр "Амфион" (ООО "НПЦ "Амфион") Фармацевтическая композиция для применения в онкологии
US10925846B2 (en) * 2014-10-10 2021-02-23 Liminal Biosciences Limited Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
CA2963354A1 (en) * 2014-10-10 2016-04-14 Prometic Biosciences Inc. Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
JP6720169B2 (ja) * 2014-11-12 2020-07-08 リミナル・バイオサイエンシーズ・リミテッドＬｉｍｉｎａｌ ＢｉｏＳｃｉｅｎｃｅｓ Ｌｉｍｉｔｅｄ 組織の自己修復及び再生のための置換芳香族化合物及び医薬組成物
CN106267213A (zh) * 2015-05-27 2017-01-04 聊城市奥润生物医药科技有限公司 环二核苷酸cGAMP在治疗肿瘤联合用药中的应用
AU2018306299B2 (en) 2017-07-25 2024-08-08 Taris Biomedical Llc Methods of treating tumor metastasis
KR20200085822A (ko) 2017-11-08 2020-07-15 타리스 바이오메디컬 엘엘씨 젬시타빈을 사용한 방광암의 치료 및 유지 요법의 방법
AU2019393347A1 (en) * 2018-12-05 2021-07-22 Liminal Biosciences Limited Use of sodium 2-(3-pentylphenyl)acetate in the treatment of alstrom syndrome
US11246945B2 (en) 2019-06-07 2022-02-15 National Defense Medical Center Cisplatin-loaded microbubbles, pharmaceutical composition for treatment of cancer, method for preparing pharmaceutical compositions and method for treating cancer
CN114436822B (zh) * 2022-01-12 2024-04-16 厦门稀土材料研究所 一枝蒿酮酸和生物碱复盐及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268907A3 (en) * 1986-11-19 1990-03-21 Carl Richard Thornfeldt Treatment of disease conditions relating to hyperactive organelles
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
ITMI20012434A1 (it) * 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
CN1169768C (zh) * 2002-04-26 2004-10-06 中国科学院上海有机化学研究所 （4－炔基）－芳香酮酸类化合物、合成方法及应用
WO2004058787A2 (en) * 2002-12-27 2004-07-15 Tibotec Bvba Fluorogenic enzyme substrates and methods of preparation
WO2005010202A2 (en) * 2003-07-16 2005-02-03 Ligand Pharmacueticals Incorporated PHENYL ACETIC ACID DERIVATIVES AS HEPATOCYTE NUCLEAR FACTOR 4α (HNF-4α) MODULATOR COMPOUNDS
WO2005009104A2 (en) * 2003-07-16 2005-02-03 Ligand Pharmacueticals Incorporated Benzoic and phenyl acetic acid derivatives as hnf-4 modulators
US8198328B2 (en) * 2004-01-21 2012-06-12 New York University Treatment of cancer using benzoic acid derivatives
DK2061452T3 (da) 2006-09-01 2012-02-13 Piramal Life Sciences Ltd Anvendelse af koffeinsyre og derivater deraf mod cancer
BRPI0807285A2 (pt) * 2007-02-08 2014-05-06 Emisphere Tech Inc "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
WO2009055932A1 (en) 2007-11-02 2009-05-07 Prometic Biosciences Inc. Substituted phenylpropionic acids as stimulators of hematopoiesis and erythropoiesis
MX338513B (es) 2007-11-02 2016-04-20 Prometic Pharma Smt Ltd Acidos grasos de longitud de cadena mediana y gliceridos como agentes de nefroprotección.
CN101903028B (zh) * 2007-12-19 2013-06-05 普罗米蒂克生物科学公司 与吉西他滨组合用于治疗胰腺癌的中等链长脂肪酸、盐类及三酸甘油酯
WO2010127440A1 (en) * 2009-05-04 2010-11-11 Prometic Biosciences Inc. Substituted aromatic compounds and pharmaceutical uses thereof
DK2427417T3 (da) * 2009-05-04 2014-01-20 Prometic Biosciences Inc Salte af 3-pentylphenyleddikesyre og farmaceutiske anvendelser deraf
CN103347509B (zh) * 2010-10-27 2016-06-08 普罗米蒂克生物科学公司 用于治疗癌症的化合物和组合物

Also Published As

Publication number Publication date
JP6007186B2 (ja) 2016-10-12
EP2632452A4 (en) 2014-05-07
KR101821646B1 (ko) 2018-01-25
BR112013010507A2 (pt) 2016-08-02
US9439882B2 (en) 2016-09-13
EA030038B1 (ru) 2018-06-29
TWI578983B (zh) 2017-04-21
US20130217645A1 (en) 2013-08-22
PT3443957T (pt) 2020-12-18
AU2011356583C1 (en) 2016-03-17
CN103347509B (zh) 2016-06-08
EP3443957B1 (en) 2020-11-25
TW201305097A (zh) 2013-02-01
EP3443957A1 (en) 2019-02-20
PH12016502324B1 (en) 2019-07-15
JP6371344B2 (ja) 2018-08-08
SG189538A1 (en) 2013-06-28
EA035494B1 (ru) 2020-06-25
MY162420A (en) 2017-06-15
EA201791585A1 (ru) 2018-05-31
US20150313856A1 (en) 2015-11-05
KR20130132448A (ko) 2013-12-04
IL225599A (en) 2017-05-29
DK3443957T3 (da) 2020-12-21
CA2816093C (en) 2020-12-01
IL225599A0 (en) 2013-06-27
EA201370103A1 (ru) 2013-12-30
MX365807B (es) 2019-06-14
AU2016201556B2 (en) 2017-09-14
TW201717928A (zh) 2017-06-01
AU2016201556A1 (en) 2016-04-14
AU2011356583A1 (en) 2013-05-09
CN103347509A (zh) 2013-10-09
MX2019007010A (es) 2019-09-06
PL3443957T3 (pl) 2021-05-04
PT2632452T (pt) 2019-01-10
CN105997967B (zh) 2019-08-23
KR20180011332A (ko) 2018-01-31
EP2632452B1 (en) 2018-09-26
CA2816093A1 (en) 2012-07-26
TWI620563B (zh) 2018-04-11
EP2632452A1 (en) 2013-09-04
WO2012097427A1 (en) 2012-07-26
PH12016502324A1 (en) 2019-07-15
JP2016188247A (ja) 2016-11-04
PL2632452T3 (pl) 2019-03-29
ZA201303035B (en) 2014-06-25
HK1189836A1 (zh) 2014-06-20
IL251083B (en) 2018-07-31
US9114118B2 (en) 2015-08-25
CL2013001152A1 (es) 2014-01-10
ES2703257T3 (es) 2019-03-07
TR201819987T4 (tr) 2019-01-21
CN105997967A (zh) 2016-10-12
JP2013544799A (ja) 2013-12-19
MX2013004832A (es) 2013-05-22
MY184343A (en) 2021-04-01
IL251083A0 (en) 2017-04-30
SG10201807622WA (en) 2018-10-30
ES2837599T3 (es) 2021-06-30
KR101943280B1 (ko) 2019-01-28
NZ610851A (en) 2015-05-29
AU2011356583B2 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
DK2632452T3 (da) Forbindelser og sammensætninger til cancerbehandling
JP7402300B2 (ja) ＮｏｔｃｈシグナリングのエンハンサーならびにＮｏｔｃｈのアップレギュレーションにより治療可能ながんおよび悪性腫瘍の治療におけるその使用
EP2367545A1 (en) Di-vanilloyl and tri-vanilloyl derivatives for use in anti-cancer therapy
BRPI1015124B1 (pt) Compostos aromáticos substituídos para a prevenção ou tratamento dedistúrbios sanguíneos; distúrbios renais, nefropatias e/ou complicações dodistúrbio renal; doenças relacionadas com inflamação; e distúrbios relacionadosao estresse oxidativo, usos farmacêuticos dos mesmos e composiçãofarmacêutica comprendendo ditos compostos
JP5235257B2 (ja) 治療化合物としての置換カルコン
AU2015330645B2 (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
EA032431B1 (ru) Производные фумагиллола
WO2023145873A1 (ja) リゾホスファチジルセリン類似体、及びリゾホスファチジルセリン類似体を含む線維症を治療又は予防するための医薬組成物
CA3195137A1 (en) Substituted aromatic compounds and pharmaceutical compositions thereof